Marksans Pharma Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Marksans Pharma de 22% y 14.6% por año respectivamente. Se prevé que el BPA crezca en un 22.1% al año. Se espera que la rentabilidad financiera sea de 16.1% en 3 años.
Información clave
22.0%
Tasa de crecimiento de los beneficios
22.06%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 16.6% |
| Tasa de crecimiento de los ingresos | 14.6% |
| Rentabilidad financiera futura | 16.14% |
| Cobertura de analistas | Low |
| Última actualización | 17 Mar 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Artículo de análisis • Feb 10
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...Artículo de análisis • Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Artículo de análisis • May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Artículo de análisis • Feb 15
Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a mediocre week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with the stock dropping 15% to...Recent updates
Artículo de análisis • Feb 10
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...Artículo de análisis • Jan 15
Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 22.2x...Artículo de análisis • Dec 09
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...
Actualización de narrativa • Nov 11
MARKSANS: Upcoming Board Meeting And UK Regulatory Success Will Drive Momentum
Analysts have reduced their price target for Marksans Pharma from ₹231.67 to ₹216.67. They cite slight increases in the discount rate and a modest drop in the company's projected future price-to-earnings ratio as reasons for the adjustment.Artículo de análisis • Oct 15
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Actualización de narrativa • Aug 15
Developed Markets Will Support Affordable Generic Expansion
Marksans Pharma's consensus price target has been revised downward, primarily due to sharply reduced revenue growth forecasts and a decline in net profit margin, lowering the fair value estimate from ₹301.00 to ₹231.67. What's in the News Board re-appointed Mr. Mark Saldanha as Managing Director, subject to shareholder approval at the upcoming AGM.Artículo de análisis • Aug 15
Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Artículo de análisis • Aug 07
Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Artículo de análisis • Jun 28
Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Marksans Pharma fair value estimate is ₹239 With ₹253 share...Artículo de análisis • May 27
We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings
Marksans Pharma Limited's ( NSE:MARKSANS ) robust recent earnings didn't do much to move the stock. However the...Artículo de análisis • May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Artículo de análisis • May 14
Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Artículo de análisis • Mar 23
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Mar 05
Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 24.6x...Artículo de análisis • Feb 15
Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a mediocre week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with the stock dropping 15% to...Artículo de análisis • Feb 01
Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Marksans Pharma's estimated fair value is ₹190 based on 2 Stage Free Cash Flow to Equity Marksans Pharma's...
Nueva narrativa • Jan 28
Teva Pharma Facility And US Expansion To Strengthen Future Outlook
Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.Artículo de análisis • Nov 27
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Marksans Pharma Limited ( NSE:MARKSANS ) shares have been powering on, with a gain of...Artículo de análisis • Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Artículo de análisis • Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Marksans Pharma Limited ( NSE:MARKSANS ) shares have continued their recent momentum with a 45% gain in the last month...Artículo de análisis • Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Marksans Pharma Limited ( NSE:MARKSANS ) shareholders would be excited to see that the share price has had a great...Artículo de análisis • Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
The market shrugged off Marksans Pharma Limited's ( NSE:MARKSANS ) solid earnings report. We did some digging and...Artículo de análisis • May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Artículo de análisis • Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider...Artículo de análisis • Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Artículo de análisis • Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • Jun 21
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2028 | 38,556 | 5,859 | 3,720 | N/A | 3 |
| 3/31/2027 | 33,750 | 4,985 | 2,871 | N/A | 3 |
| 3/31/2026 | 28,996 | 3,893 | 2,927 | N/A | 3 |
| 12/31/2025 | 28,033 | 3,603 | N/A | N/A | N/A |
| 9/30/2025 | 27,307 | 3,517 | 346 | 2,047 | N/A |
| 6/30/2025 | 26,522 | 3,501 | N/A | N/A | N/A |
| 3/31/2025 | 26,228 | 3,806 | 337 | 2,067 | N/A |
| 12/31/2024 | 24,744 | 3,683 | N/A | N/A | N/A |
| 9/30/2024 | 23,787 | 3,470 | 520 | 2,169 | N/A |
| 6/30/2024 | 22,680 | 3,338 | N/A | N/A | N/A |
| 3/31/2024 | 21,774 | 3,137 | 216 | 2,304 | N/A |
| 12/31/2023 | 21,034 | 3,164 | N/A | N/A | N/A |
| 9/30/2023 | 19,971 | 2,965 | 894 | 2,528 | N/A |
| 6/30/2023 | 19,184 | 2,743 | N/A | N/A | N/A |
| 3/31/2023 | 18,521 | 2,663 | 1,838 | 2,374 | N/A |
| 12/31/2022 | 17,842 | 2,123 | N/A | N/A | N/A |
| 9/30/2022 | 16,670 | 2,004 | 972 | 1,286 | N/A |
| 6/30/2022 | 15,756 | 1,847 | N/A | N/A | N/A |
| 3/31/2022 | 14,908 | 1,868 | 529 | 993 | N/A |
| 12/31/2021 | 14,069 | 2,367 | N/A | N/A | N/A |
| 9/30/2021 | 14,026 | 2,473 | 883 | 1,336 | N/A |
| 6/30/2021 | 14,064 | 2,518 | N/A | N/A | N/A |
| 3/31/2021 | 13,762 | 2,385 | 1,322 | 1,786 | N/A |
| 12/31/2020 | 13,817 | 2,018 | N/A | N/A | N/A |
| 9/30/2020 | 13,142 | 1,724 | 1,839 | 2,478 | N/A |
| 6/30/2020 | 12,203 | 1,476 | N/A | N/A | N/A |
| 3/31/2020 | 11,344 | 1,208 | 1,734 | 2,333 | N/A |
| 12/31/2019 | 10,463 | 879 | N/A | N/A | N/A |
| 9/30/2019 | 9,972 | 834 | N/A | 416 | N/A |
| 6/30/2019 | 10,099 | 780 | N/A | N/A | N/A |
| 3/31/2019 | 10,001 | 804 | N/A | 274 | N/A |
| 12/31/2018 | 9,523 | 666 | N/A | N/A | N/A |
| 9/30/2018 | 9,223 | 582 | N/A | N/A | N/A |
| 6/30/2018 | 9,272 | 463 | N/A | N/A | N/A |
| 3/31/2018 | 9,127 | 358 | N/A | 501 | N/A |
| 12/31/2017 | 8,918 | 343 | N/A | N/A | N/A |
| 9/30/2017 | 8,949 | 275 | N/A | N/A | N/A |
| 6/30/2017 | 8,015 | 187 | N/A | N/A | N/A |
| 3/31/2017 | 7,672 | 113 | N/A | 141 | N/A |
| 12/31/2016 | 7,926 | 70 | N/A | N/A | N/A |
| 9/30/2016 | 7,948 | 136 | N/A | N/A | N/A |
| 6/30/2016 | 8,699 | 481 | N/A | N/A | N/A |
| 3/31/2016 | 8,933 | 785 | N/A | 308 | N/A |
| 12/31/2015 | 8,536 | 1,093 | N/A | N/A | N/A |
| 9/30/2015 | 8,495 | 1,191 | N/A | N/A | N/A |
| 6/30/2015 | 8,045 | 1,154 | N/A | N/A | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (22% al año) de MARKSANS es superior a la tasa de ahorro (6.9%).
Beneficios vs. Mercado: Se prevé que los beneficios (22% al año) de MARKSANS crezcan más rápidamente que el mercado Indian (16.3% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de MARKSANS crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (14.6% al año) de MARKSANS crezcan más rápidamente que los del mercado Indian (10.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 14.6% al año) de MARKSANS crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de MARKSANS sea baja dentro de 3 años (16.1%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 06:23 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Marksans Pharma Limited está cubierta por 5 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Ranjit Kapadia | Centrum Broking Limited |
| Deepika Murarka | Choice Equity Broking Private Limited |
| Maitri Sheth | Choice Equity Broking Private Limited |